Replies to post #141522 on Biotech Values

[iwfal]

SNTA -

the LDH low/normal vs high stratification is across all patients, irrespective of histology or other mutations.

Agreed that the pre-defined subgroups being used by Synta are likely to be overlapping subgroups - given that they appear to be targetting 90% powerings

It is interesting that so many dismiss the INFI HSP90 inhibitor, due to it's being "first generation" and having flamed out already in one clinical trial and being ditched by Medimmune.

I haven't looked for liver tox - but in theory that should be the killer for this, a first gen drug.